Positive sentinel node in breast cancer – when and why also opt for axillary dissection?

Česká verzia

Authors: P. Krsička ^1,2; O. Coufal ^1,2 ; O. Zapletal
Authors place of work: Masarykův onkologický ústav, Brno ; Oddělení chirurgické onkologie, přednosta: Prim. MUDr. Z. Eber ¹; Klinika komplexní onkologické péče, přednosta: Prof. MUDr. R. Vyzula, CSc. ²
Published in the journal: Rozhl. Chir., 2013, roč. 92, č. 12, s. 684-689.
Category: Review

Práce je věnována prof. MUDr. Janu Wechslerovi u příležitosti jeho 75. narozenin

Summary

One of the central concerns of contemporary mammary surgery is to verify the actual need for axillary dissection (AD) in patients with early breast cancer and positive sentinel lymph node biopsy. Several studies have addressed this issue (ASOCOG Z0011, IBCSG 23-01, MIRROR, EORTC AMAROS). So far, the preliminary results of the ASOCOG Z0011 trial with a median follow-up of 6.3 years and the results of the IBCSG 23-01 trial with a median follow-up of 5 years have been published. The conclusions of both randomized studies have implied that under specific circumstances, there is no significant difference in the local or regional recurrence between patients who had undergone completion AD compared to the patients in whom AD had been omitted. This article summarizes the current knowledge regarding indications for AD in patients with positive sentinel nodes.

Key words:
breast cancer – sentinel lymph node biopsy – axillary lymph node dissection – ACOSOG Z0011 trial

Zdroje

1. Sobin LH, Gospodarowicz MK, Wittekind CH. TNM klasifikace zhoubných novotvarů. 7. Vydání 2009, Ústav zdravotnických informací a statistiky, česká verze 2011.

2. Moore KH, Thaler HT, Tan LK, Borgen PI, Cody HS. Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artefact? Cancer 2004;100:929–934.

3. ASCO Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: Guideline Summary. J Oncol Pract 2005;1:134–136.

4. de Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009;361:653–63.

5. Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011;306:385–93.

6. Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011;364:412–21.

7. The American Society of Breast Surgeons. Position Statement on Management of the Axilla in Patients With Invasive Breast Cancer. Dostupný na https://www.breastsurgeons.org/statements/PDF_Statements/Axillary_Management.pdf>.

8. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013;14:297–305.

9. Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, et al. Trends in and outcomes from sentinel lymf node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patiens: experience from the SEER diabase. Ann Surg Oncol 2010;17 Suppl3:343–51.

10. Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003;10:1140–51.

11. Coufal O, Pavlik T, Fabian P, Bori R, Boross G, et al. Predicting Non-Sentinel Lymph Node Status After Positive Sentinel Biopsy in Breast Cancer: What Model Performs the Best in a Czech Population? Pathology & Oncology Research 2009;15:733–40.

12. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569–75.

13. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252:426–32.

14. Giuliano AE. ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1–2 N0M0 breast cancer who have a positive sentinel node. ASCO Annual Meeting 2010, CRA506.

15. Gatzemeier W, Bruce Mann G. Which sentinel lymph-node (SLN) positive breast cancer patient needs an axillary lymph-node dissection (ALND) – ACOSOG Z0011 results and beyond. Breast 2013:S0960-9776(13)00032–5.

16. Giuliano AE, Morrow M, Duggal S, Julian TB. Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer? Clin Exp Metastasis 2012;29:687–92.

17. Grant M, Harbeck N, Thomssen Ch. St. Gallen 2011: Summary of the Consensus Discussion. Breast Care, Basel 2011; 6:136–141.

18. Montemurro F, Maggiorotto F, Valabrega G, Kubatzki F, Rossi V, et al. Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients. Ann Surg Oncol 2012;19:3755–61.

19. Straver ME, Meijnen P, van Tienhoven G, et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol 2010;28:731–7.

20. Setton J, et al: Radiation Field Design and Regional Control in Sentinel Lymph Node-Positive Breast Cancer Patients With Omission of Axillary Dissection. Cancer 2012;118:1994–2003.

21. Morrow M, Giuliano AE. To cut is to cure: can we really apply Z11 in practice? Ann Surg Oncol 2011;18:2413–5.

22. Galimberti V, Chifu C, Rodriguez Perez S, Veronesi P, Intra M,et al. Positive axillary sentinel lymph node: is axillary dissection always necessary? Breast 2011;20,Suppl3:S96–8.

23. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, et al. Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736–47.

24. Pazaiti A, Fentiman IS. Which patients need an axillary clearance after sentinel node biopsy? Int J Breast Cancer 2011:195892. doi: 10.4061/2011/195892. Epub 2011 Aug 24.

25. Kotoč J, Kotočová K, Gatěk J, Duben J, Vážan P, et al. Mikrometastáza v sentinelové uzlině – nutnost disekce axilárních uzlin? Prakt Lék 2009;89:587–590.

26. Coufal O, Fait V. Chirurgická léčba karcinomu prsu. Praha, Grada 2011:207–52.

27. Gatek J, Vrana D, Hnatek L, Bakala J, Dudesek B, et al. Sentinel node biopsy and neoadjuvant chemotherapy in the treatment of breast cancer. J BUON 2012;17:265–70.

28. Coufal O, Vrtelova P, Krsicka P. Operace mízních uzlin u karcinomů prsu – současný pohled. Postgraduální medicína 2012;14: 376–383.

29. Zapletal O, Coufal O, Selingerová I, Krsička P, Vrtělová P. The number of removed axillary sentinel lymph nodes and its impact on the diagnostic accuracy of sentinel lymph node biopsy in breast cancer. Rozhl Chir 2013;92:21–6.

30. Fait V, Coufal O, Gatěk J. Chirurgie karcinomu prsu v České republice. Rozhl Chir 2010;89:229–230.